| Characteristic | Rinvoq (AbbVie) Jak1 (Ph3) | Stelara (J&J) IL-12/IL-23 MAb (Marketed) | Zeposia (BMS) S1P receptor modulator (Approved) | Entyvio (Takeda) Alpha-4 beta-7 integrin antibody (Marketed) | Mirikizumab (Lilly) IL-23 MAb (Ph3) |
|---|---|---|---|---|---|
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
| - | - | - | - | - | - |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Download
Sources
Release date
May 2021
Region
Worldwide
Survey time period
as of May 2021
Citation formats









